In the following video, Brenton Flynn sits down with Fool.com analyst Brendan Byrnes to discuss a topic that's gathered considerable attention in recent years: orphan drug development. In particular, they discuss the reasons for this focus, as well as an interesting scenario in which a very small patient market has become saturated with options.
The future of MannKind?
While diabetes is far from an orphan disease, there's one company pursuing something extraordinary in the space. Will MannKind's disruptive technology revolutionize the way diabetes is treated around the world -- or will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more -- and get a full year of free updates -- click here to grab your copy today.